Literature DB >> 16495579

Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues.

Miho Watanabe1, Katsura Igai, Koji Matsuoka, Atsushi Miyagawa, Toshiyuki Watanabe, Ryohei Yanoshita, Yuji Samejima, Daiyo Terunuma, Yasuhiro Natori, Kiyotaka Nishikawa.   

Abstract

We previously developed linear polymers bearing clustered trisaccharides of globotriaosylceramide (Gb3) as orally applicable Shiga toxin (Stx) neutralizers. Here, using a Gb3 polymer with a short spacer tethering the trisaccharide to the core, we found that shortening the spacer length markedly reduced the binding affinity for Stx2 but not Stx1. Moreover, mutational analysis revealed that the essential binding sites of the terminal trisaccharides were completely different between Stx1 and Stx2. These results provide the molecular basis for the interaction between Stx B subunits and Gb3 polymers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495579      PMCID: PMC1418665          DOI: 10.1128/IAI.74.3.1984-1988.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation.

Authors:  Kiyotaka Nishikawa; Koji Matsuoka; Miho Watanabe; Katsura Igai; Kumiko Hino; Ken Hatano; Akihiro Yamada; Nobuhisa Abe; Daiyo Terunuma; Hiroyoshi Kuzuhara; Yasuhiro Natori
Journal:  J Infect Dis       Date:  2005-05-11       Impact factor: 5.226

2.  Self-assembled monolayers of globotriaosylceramide (Gb3) mimics: surface-specific affinity with shiga toxins.

Authors:  Yoshiko Miura; Yuuki Sasao; Hirofumi Dohi; Yoshihiro Nishida; Kazukiyo Kobayashi
Journal:  Anal Biochem       Date:  2002-11-01       Impact factor: 3.365

3.  Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands.

Authors:  P I Kitov; J M Sadowska; G Mulvey; G D Armstrong; H Ling; N S Pannu; R J Read; D R Bundle
Journal:  Nature       Date:  2000-02-10       Impact factor: 49.962

4.  A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.

Authors:  Kiyotaka Nishikawa; Koji Matsuoka; Eiji Kita; Noriko Okabe; Masashi Mizuguchi; Kumiko Hino; Shinobu Miyazawa; Chisato Yamasaki; Junken Aoki; Sachio Takashima; Yoshio Yamakawa; Masahiro Nishijima; Daiyo Terunuma; Hiroyoshi Kuzuhara; Yasuhiro Natori
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1.

Authors:  Anna M Soltyk; C Roger MacKenzie; Vince M Wolski; Tomoko Hirama; Pavel I Kitov; David R Bundle; James L Brunton
Journal:  J Biol Chem       Date:  2001-11-26       Impact factor: 5.157

6.  Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands.

Authors:  George L Mulvey; Paola Marcato; Pavel I Kitov; Joanna Sadowska; David R Bundle; Glen D Armstrong
Journal:  J Infect Dis       Date:  2003-02-07       Impact factor: 5.226

7.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Authors:  Richard L Siegler; Tom G Obrig; Theodore J Pysher; Vernon L Tesh; Nathaniel D Denkers; Fletcher B Taylor
Journal:  Pediatr Nephrol       Date:  2003-01-10       Impact factor: 3.714

8.  Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7.

Authors:  Marie E Fraser; Masao Fujinaga; Maia M Cherney; Angela R Melton-Celsa; Edda M Twiddy; Alison D O'Brien; Michael N G James
Journal:  J Biol Chem       Date:  2004-04-09       Impact factor: 5.157

9.  Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

Authors:  M A Karmali; B T Steele; M Petric; C Lim
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

10.  Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.

Authors:  Miho Watanabe; Koji Matsuoka; Eiji Kita; Katsura Igai; Nobutaka Higashi; Atsushi Miyagawa; Toshiyuki Watanabe; Ryohei Yanoshita; Yuji Samejima; Daiyo Terunuma; Yasuhiro Natori; Kiyotaka Nishikawa
Journal:  J Infect Dis       Date:  2004-01-21       Impact factor: 5.226

View more
  8 in total

1.  An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin.

Authors:  Miho Watanabe-Takahashi; Toshio Sato; Taeko Dohi; Noriko Noguchi; Fumi Kano; Masayuki Murata; Takashi Hamabata; Yasuhiro Natori; Kiyotaka Nishikawa
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

Review 2.  Shiga Toxin (Stx) Classification, Structure, and Function.

Authors:  Angela R Melton-Celsa
Journal:  Microbiol Spectr       Date:  2014-08

3.  The crystal structure of shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor.

Authors:  Jared M Jacobson; Jiang Yin; Pavel I Kitov; George Mulvey; Tom P Griener; Michael N G James; Glen Armstrong; David R Bundle
Journal:  J Biol Chem       Date:  2013-11-13       Impact factor: 5.157

4.  Shiga toxin suppresses noncanonical inflammasome responses to cytosolic LPS.

Authors:  Morena S Havira; Atri Ta; Puja Kumari; Chengliang Wang; Ashley J Russo; Jianbin Ruan; Vijay A Rathinam; Sivapriya Kailasan Vanaja
Journal:  Sci Immunol       Date:  2020-11-27

5.  Affinity-Based Screening of Tetravalent Peptides Identifies Subtype-Selective Neutralizers of Shiga Toxin 2d, a Highly Virulent Subtype, by Targeting a Unique Amino Acid Involved in Its Receptor Recognition.

Authors:  Takaaki Mitsui; Miho Watanabe-Takahashi; Eiko Shimizu; Baihao Zhang; Satoru Funamoto; Shinji Yamasaki; Kiyotaka Nishikawa
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

6.  Fighting Shigella by Blocking Its Disease-Causing Toxin.

Authors:  Diksha Haksar; Mostafa Asadpoor; Torben Heise; Jie Shi; Saskia Braber; Gert Folkerts; Lluis Ballell; Janneth Rodrigues; Roland J Pieters
Journal:  J Med Chem       Date:  2021-04-28       Impact factor: 7.446

7.  Glycolipid binding preferences of Shiga toxin variants.

Authors:  Sayali S Karve; Alison A Weiss
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

Review 8.  Verotoxin Receptor-Based Pathology and Therapies.

Authors:  Clifford Lingwood
Journal:  Front Cell Infect Microbiol       Date:  2020-03-31       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.